NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport(University of Maryland, Baltimore), Edward A. Stadtmauer(University of Pennsylvania), Gwendolyn Binder-Scholl(Adaptimmune (United Kingdom)), Olga Goloubeva(University of Maryland, Baltimore), Dan T. Vogl(University of Pennsylvania), Simon F. Lacey(University of Pennsylvania), Ashraf Badros(University of Maryland, Baltimore), Alfred L. Garfall(University of Pennsylvania), Brendan M. Weiss(University of Pennsylvania), Jeffrey Finklestein(University of Maryland, Baltimore), Irina Kulikovskaya(University of Pennsylvania), Sanjoy K. Sinha(Carleton University), Shari S. Kronsberg(University of Maryland, Baltimore), Minnal Gupta(University of Pennsylvania), Sarah Bond(Boston Biomedical (United States)), Luca Melchiori(Adaptimmune (United Kingdom)), Joanna E. Brewer(Adaptimmune (United Kingdom)), Alan Bennett(Adaptimmune (United Kingdom)), Andrew B. Gerry(Adaptimmune (United Kingdom)), Nicholas J. Pumphrey(Adaptimmune (United Kingdom)), Daniel Williams(Adaptimmune (United Kingdom)), Helen K Tayton- Martin(Adaptimmune (United Kingdom)), Lilliam Ribeiro(Adaptimmune (United Kingdom)), Tom Holdich(Adaptimmune (United Kingdom)), Saul Yanovich(University of Maryland, Baltimore), Nancy M. Hardy(University of Maryland, Baltimore), Jean A. Yared(University of Maryland, Baltimore), Naseem Kerr(University of Pennsylvania), Sunita Philip(University of Maryland, Baltimore), Sandra Westphal(University of Maryland, Baltimore), Don L. Siegel(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Bent K. Jakobsen(Adaptimmune (United Kingdom)), Michael Kalos(University of Pennsylvania), Carl H. June(University of Pennsylvania)
Cited by 844Open Access